Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease

American Journal of Respiratory Cell and Molecular Biology

Volumn 46, Issue 5, 2012, Pages 614-622

  Wang, Lei ^a   Yang, Jun ^a   Guo, Lei ^a   Uyeminami, Dale ^a   Dong, Hua ^a   Hammock, Bruce D ^a   Pinkerton, Kent E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Airway obstruction; Anti inflammatory agents; Experimental animal models

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; 4 [4 [3 (4 TRIFLUOROMETHOXY PHENYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; 5 OXO 6,8,11,14 ICOSATETRAENOIC ACID; ENZYME INHIBITOR; GAMMA INTERFERON; ICOSATETRAENOIC ACID; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; MUCIN; PROSTAGLANDIN E2; ROLIPRAM; TOBACCO SMOKE; UNCLASSIFIED DRUG; VASCULOTROPIN;

AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; LUNG COMPLIANCE; LUNG LAVAGE; LUNG RESISTANCE; MACROPHAGE; MALE; MUCUS SECRETION; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; BENZOATES; BODY WEIGHT; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; ENZYME INHIBITORS; EPOXIDE HYDROLASES; PHENYLUREA COMPOUNDS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; ROLIPRAM; SMOKE; TOBACCO;

ANIMALIA; NICOTIANA TABACUM; RATTUS;

EID: 84860511513     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0359OC     Document Type: Article

References (45)

1. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012. (Pubitemid 38269277)
2. Fox JC, Fitzgerald MF. The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPD. Curr Opin Pharmacol 2009;9:231-242.
3. Kubo S, Kobayashi M, Iwata M, Takahashi K, Miyata K, Shimizu Y. Disease-modifying effect of ASP3258, a novel phosphodiesterase Type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs. Eur J Pharmacol 2011;659:79-84.
4. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001;46:798-825. (Pubitemid 33759920)
5. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-688. (Pubitemid 37258549)
6. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-1309. (Pubitemid 32506590)
7. Hele DJ, Belvisi MG. Novel therapies for the treatment of inflammatory airway disease. Expert Opin Investig Drugs 2003;12:5-18. (Pubitemid 36104639)
8. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743.
9. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-695. (Pubitemid 39258317)
10. Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P. Roflumilast. Nat Rev Drug Discov 2010;9:761-762.
11. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006;129:56-66. (Pubitemid 43265243)
12. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-161. (Pubitemid 47057851)
13. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279. (Pubitemid 29398616)
14. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007;292:C996-C1012. (Pubitemid 46442641)
15. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 2007;82:42-49. (Pubitemid 44880165)
16. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II - induced hypertension. Hypertension 2005;45:759-765. (Pubitemid 40418378)
17. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006;103:18733-18738. (Pubitemid 44913479)
18. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, Hammock BD. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006;103:13646-13651. (Pubitemid 44413961)
19. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke - induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005;102:2186-2191. (Pubitemid 40262033)
20. Teague SV, Pinkerton KE, Goldsmith M, Gebremichael A, Chang S, Jenkins RA, Moneyhun JH. Sidestream cigarette smoke generation and exposure system for environmental tobacco smoke studies. Inhal Toxicol 1994;6:79-93. (Pubitemid 2051383)
21. Smith KR, Uyeminami DL, Kodavanti UP, Crapo JD, Chang LY, Pinkerton KE. Inhibition of tobacco smoke - induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med 2002;33:1106-1114.
22. Yang J, Schmelzer K, Georgi K, Hammock BD. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 2009;81: 8085-8093.
23. Bolton SJ, Pinnion K, Oreffo V, Foster M, Pinkerton KE. Characterisation of the proximal airway squamous metaplasia induced by chronic tobacco smoke exposure in spontaneously hypertensive rats. Respir Res 2009;10:118.
24. Zhong CY, Zhou YM, Pinkerton KE. NF-kappaB inhibition is involved in tobacco smoke - induced apoptosis in the lungs of rats. Toxicol Appl Pharmacol 2008;230:150-158.
25. Zheng H, Liu Y, Huang T, Fang Z, Li G, He S. Development and characterization of a rat model of chronic obstructive pulmonary disease (COPD) induced by sidestream cigarette smoke. Toxicol Lett 2009;189:225-234.
26. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653. (Pubitemid 38787999)
27. Spond J, Chapman R, Fine J, Jones H, Kreutner W, Kung TT, Minnicozzi M. Comparison of PDE 4 inhibitors, Rolipram and SB 207499 (Ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 2001;14:157-164. (Pubitemid 32553621)
28. Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH, Hammock BD. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci 2006;79:2311-2319. (Pubitemid 44666069)
29. Benoit C, Renaudon B, Salvail D, Rousseau E. EETs relax airway smooth muscle via an EpDHF effect: BK(Ca) channel activation and hyperpolarization. Am J Physiol Lung Cell Mol Physiol 2001;280:L965-L973.
30. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am J Respir Cell Mol Biol 2008; 38:192-201. (Pubitemid 351162841)
31. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, Hammock BD. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006;103:13646-13651. (Pubitemid 44413961)
32. Henricks PA, Engels F, van der Linde HJ, Garssen J, Nijkamp FP. 13-Hydroxy - linoleic acid induces airway hyperresponsiveness to histamine and methacholine in guinea pigs in vivo. J Allergy Clin Immunol 1995;96:36-43.
33. Powell WS, Rokach J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res 2005;44:154-183. (Pubitemid 40733083)
34. O'Donnell RA, Richter A, Ward J, et al. Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax 2004; 59:1032-1040. (Pubitemid 39573921)
35. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 2004;59:992-996. (Pubitemid 39490787)
36. Gensch E, Gallup M, Sucher A, Li D, Gebremichael A, Lemjabbar H, Mengistab A, Dasari V, Hotchkiss J, Harkema J, et al. Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK. J Biol Chem 2004;279:39085-39093. (Pubitemid 39296071)
37. Choi WI, Syrkina O, Kwon KY, Quinn DA, Hales CA. JNK activation is responsible for mucus overproduction in smoke inhalation injury. Respir Res 2010;11:172-179.
38. Mata M, Sarriá B, Buenestado A, Cortijo J, Cerdá M, Morcillo EJ. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-152. (Pubitemid 40222898)
39. Guerassimov A, Hoshino Y, Takubo Y, Turcotte A, Yamamoto M, Ghezzo H, Triantafillopoulos A, Whittaker K, Hoidal JR, Cosio MG. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med 2004;170:974-980. (Pubitemid 39425693)
40. Cukić V, Maglajlić J. Body weight loss in patients with chronic obstructive pulmonary disease. Med Arh 2007;61:175-181.
41. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-1156. (Pubitemid 23149871)
42. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:347-360. (Pubitemid 36204553)
43. American Thoracic Society, European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: a statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999;159(Suppl.):S1-S40.
44. Keseru B, Barbosa-Sicard E, Popp R, Fisslthaler B, Dietrich A, Gudermann T, Hammock BD, Falck JR, Weissmann N, Busse R. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J 2008;22:4306-4315.
45. Pokreisz P, Fleming I, Kiss L, Barbosa-Sicard E, Fisslthaler B, Falck JR, Hammock BD, Kim IH, Szelid Z, Vermeersch P. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 2006;47:762-770. (Pubitemid 43740249)